Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
FibroGen
Fierce Biotech
FibroGen pays SEC $1.2M over claims of 'reverse engineered' data
FibroGen has agreed to pay $1.25 million to the SEC to settle allegations that its former chief medical officer manipulated data for the anemia drug.
James Waldron
Sep 11, 2025 10:41am
Novo Nordisk, AstraZeneca, Ono—Fierce Pharma Asia
Feb 21, 2025 8:45am
AstraZeneca pays $160M for FibroGen's China unit
Feb 20, 2025 8:36am
Novartis, Neurocrine-Takeda, Enhertu—Fierce Pharma Asia
Apr 26, 2024 5:45am
FibroGen, Kind Pharma settle trade secrets theft dispute
Apr 19, 2024 12:53pm
Leqembi, Takeda, Fujifilm Diosynth—Fierce Pharma Asia
Apr 19, 2024 9:20am
